ArticleEuropean journal of neurology2021
Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival.
Article in European journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review.Clinical neurology and neurosurgery · 2022Pooled it
- Anxiety in Myasthenia Gravis Patients Throughout the COVID-19 Pandemic-Prevalence, Risk Factors, and Association With Vaccination Status.Brain and behavior · 2025Article
- Myasthenia gravis and community-acquired pneumonia: therapeutic challenges.Frontiers in pharmacology · 2025Review
- The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis.Vaccines · 2024Article
- The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection.Brain and behavior · 2024Article
- COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Impact of COVID-19 Infection and Its Association With Previous Vaccination in Patients With Myasthenia Gravis in Korea: A Multicenter Retrospective Study.Journal of Korean medical science · 2024Article
- Review
- Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Observational
- Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients.Journal of inflammation research · 2024Article
- Autoimmune myasthenia gravis and COVID-19. A case report-based review.The Journal of international medical research · 2023Review
- An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Observational
- Myasthenia gravis, respiratory function, and respiratory tract disease.Journal of neurology · 2023Review
- Health-related quality of life (HRQoL) and psychological impact of the COVID-19 pandemic on patients with myasthenia gravis.Intractable & rare diseases research · 2023Article
- Comparing the Impact of COVID-19 on Vaccinated and Unvaccinated Patients Affected by Myasthenia Gravis.Life (Basel, Switzerland) · 2023Article
- Outcomes of COVID-19 Infection and Vaccination Among Individuals With Myasthenia Gravis.JAMA network open · 2023Article
- COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis.Acta neurologica Belgica · 2023Article
- Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular COVID-19 Registry.European journal of neurology · 2023Article
- Clinical Characteristics of Myasthenia Gravis Patients with COVID-19 in Guangxi, China: A Case-Control Study.Journal of inflammation research · 2023Article
- Neuromuscular Disorders Associated With COVID-19.Neuroscience insights · 2023Review
Corrections and comments
- Commented on by
- Erratum issuedCorrigendum.2022
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
background and purposeMyasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID-19) mainly due to respiratory muscle weakness, older age and long-term immunosuppressive treatment. We aimed to define factors predicting the severity of COVID-19 in MG patients and risk of MG exacerbation during COVID-19.
methodsWe evaluated clinical features and outcomes after COVID-19 in 93 MG patients.
resultsThirty-five patients (38%) had severe pneumonia and we recorded 10 deaths (11%) due to COVID-19. Higher forced vital capacity (FVC) values tested before COVID-19 were shown to be protective against severe infection (95% CI 0.934-0.98) as well as good control of MG measured by the quantified myasthenia gravis score (95% CI 1.047-1.232). Long-term chronic corticosteroid treatment worsened the course of COVID-19 in MG patients (95% CI 1.784-111.43) and this impact was positively associated with dosage (p = 0.005). Treatment using azathioprine (95% CI 0.448-2.935), mycophenolate mofetil (95% CI 0.91-12.515) and ciclosporin (95% CI 0.029-2.212) did not influence the course of COVID-19. MG patients treated with rituximab had a high risk of death caused by COVID-19 (95% CI 3.216-383.971). Exacerbation of MG during infection was relatively rare (15%) and was not caused by remdesivir, convalescent plasma or favipiravir (95% CI 0.885-10.87).
conclusionsAs the most important predictors of severe COVID-19 in MG patients we identified unsatisfied condition of MG with lower FVC, previous long-term corticosteroid treatment especially in higher doses, older age, the presence of cancer, and recent rituximab treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.